Investor’s Delight: Verona Pharma Plc ADR (VRNA) Closes Weak at 29.60, Down -1.30

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Verona Pharma Plc ADR (NASDAQ: VRNA) was $29.60 for the day, down -1.30% from the previous closing price of $29.99. In other words, the price has decreased by -$1.30 from its previous closing price. On the day, 1.02 million shares were traded. VRNA stock price reached its highest trading level at $30.46 during the session, while it also had its lowest trading level at $28.845.

Ratios:

Our analysis of VRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.61 and its Current Ratio is at 8.61. In the meantime, Its Debt-to-Equity ratio is 1.30 whereas as Long-Term Debt/Eq ratio is at 1.29.

On August 26, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $31.Piper Sandler initiated its Overweight rating on August 26, 2022, with a $31 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 11 ’24 when ZACCARDELLI DAVID sold 600,000 shares for $3.76 per share. The transaction valued at 2,254,320 led to the insider holds 15,250,704 shares of the business.

Hahn Mark W sold 600,000 shares of VRNA for $2,254,080 on Sep 11 ’24. The Chief Financial Officer now owns 14,339,688 shares after completing the transaction at $3.76 per share. On Sep 11 ’24, another insider, MARK HAHN , who serves as the Officer of the company, bought 75,000 shares for $28.04 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 2404561920 and an Enterprise Value of 18954082304.

Stock Price History:

Over the past 52 weeks, VRNA has reached a high of $30.73, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 16.87%, while the 200-Day Moving Average is calculated to be 61.04%.

Shares Statistics:

VRNA traded an average of 1.45M shares per day over the past three months and 1018310 shares per day over the past ten days. A total of 80.44M shares are outstanding, with a floating share count of 62.79M. Insiders hold about 22.56% of the company’s shares, while institutions hold 62.24% stake in the company. Shares short for VRNA as of 1724976000 were 9009436 with a Short Ratio of 6.22, compared to 1722384000 on 8842639. Therefore, it implies a Short% of Shares Outstanding of 9009436 and a Short% of Float of 11.58.

Most Popular